STAT Bulletin. Drug Therapy Guideline Updates. To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business
|
|
- Shon Harrington
- 5 years ago
- Views:
Transcription
1 STAT Bulletin November 28, 2011 Volume 17: Issue 34 To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business Drug Therapy Guideline Updates Why you re receiving this Stat The attached Drug Therapy Guidelines are effective January 1, These updates are a result of the annual guideline review and new drug evaluations performed quarterly by our Pharmacy and Therapeutics Committee, or as a result of new medications entering the market. What you need to know The updated Drug Therapy Guidelines will be available for review online as of December 1, 2011 at bcbswny.com. Select I m a Provider > Tools and Resources > Pharmacy Services. What you need to do If you do not have access to the internet, paper copies are available, upon request, as of December 1, by calling Provider Service at or HNNY CC1624 1
2 Prescription Drug/Policy Sylatron Non-Formulary ication Coverage Exceptions Adcetris New Guidelines Policy Summary (See guidelines for all specifics) Covered for FDA-approved indication of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy (full Sylatron policy found in the Drug Therapy Guidelines: Abbreviated Criteria document on our website) Considerations used to determine coverage when requests for non-formulary medications are submitted are outlined in this policy Covered for FDA-approved indication (per the Global Authorization Criteria) or Actemra Drug Therapy Guideline Title Actimmune Amevive Guidelines with changes that will impact the review process Policy Criteria Changes Summary (See guidelines for specifics) Dosage information added with regards to ANC, plts, and AST/ALT Lab values required for renewal are more lenient Specialist criteria added to the policy Hematologist, immunologist, infectious disease specialist for chronic granulomatous disease Endocrinologist for osteopetrosis Addition of diagnostic criteria Addition of specific requirements for other therapies (topical, oral, biologic, photo) first (including both Enbrel and Humira) Addition of specialist requirements Addition of age requirements 2 or Ampyra No changes Antinarcoleptic Agents Specialist notes/polysomnography required for narcolepsy diagnosis if not requested by a neurologist or pulmonologist Coverage duration for narcolepsy increased to 2 years Apokyn Policy abolished Benign Prostatic Hyperplasia (BPH) Therapy No changes Changed wording from chronic daily headache to wording as found in the Botox Prescribing Information
3 Drug Therapy Guideline Title Botulinum Toxins Policy Criteria Changes Summary (See guidelines for specifics) Indication Included specific examples of first line therapies for hyperhidrosis Coverage for the treatment of plantar hyperhidrosis considered investigational and not covered Coverage for sialorrhea available when associated with neurological disorders Policy exclusion list limited Criteria added for coverage in piriformis syndrome Renewal criteria specified as same as initial criteria Approval duration extended 3 or Colony Stimulating Factors Enbrel No changes Erectile Dysfunction Coverage duration increased Agents Daily dosing covered for Cialis 2.5mg and 5mg tablets Forteo Requirement of diagnostic DXA scan and/or FRAX score added Gonadotropin-Releasing Hormone Agonist Requirement of iron usage timeframes added for anemia secondary to uterine leiomyomata Quantity allowances and coverage duration revised Removal of diagnosis from autopay, will now be reviewed Central precocious puberty (259.1) no longer autopay diagnosis, will be reviewed o Coverage criteria outlined based on age o Renewal criteria outlined based on age Clarification of pharmacy benefit vs. medical benefit made Coverage criteria for breast and ovarian cancers included Humira No changes Idiopathic / Thrombocytopenia Purpura (ITP) Agents No changes Incretin Mimetics Trial with Byetta no longer required for coverage of Victoza Injectable Fertility No changes ications Inspra Policy abolished Approval duration extended Intranasal Steroids Triamcinolone added as preferred agent Nasarel, Nasacort AQ removed from policy Iressa Recommendation to abolish policy based on lack of inappropriate and low use Leukotriene Receptor Antagonists
4 Drug Therapy Guideline Title Policy Criteria Changes Summary (See guidelines for specifics) or Nutritional Supplements No changes Orencia Addition of Orencia SC to the policy / Proton Pump Inhibitors (PPIs) Coverage of non-preferred PPIs require trial with preferred agents at maximum dosing (i.e. twice daily) with failure to provide benefit Pulmonary Arterial Hypertension (PAH) Agents Addition of Veletri to policy Removal of Black Box warning from Letairis Implement prior authorization reviews of Ventavis, Flolan, and Veletri Clarification of pharmacy vs. medical benefit made / RANKL Inhibitors Addition of diagnostic criteria for osteoporosis Sedative Hypnotics No changes Selective Serotonin Reuptake Inhibitors Requirement of trial with at least two generic SSRIs first This represents a change from old policy for Lexapro, which required two generic SSRIs, one of which must have been citalopram Based on indication of and new safety concerns with citalopram, policy changed to allow for any two generics Addition of GIST coverage Gleevec trial required prior to coverage for CML Sprycel accelerated or blast crisis phase Requirement of Ph+ or BCR/ABL+ verification for first line use in CML in chronic phase Coverage criteria added for pancreatic neuroendocrine Sutent tumor treatment, soft tissue sarcoma treatment, and thyroid carcinoma treatment Tasigna Specific criteria outlined for each phase of CML Testosterone Replacements Topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Approval duration extended Initial coverage duration for Voltaren Gel and Pennsaid extended Urinary Agents Approval duration extended 4
5 Auto-Pay ICD-9 Codes for Selected ical ications Some medical benefit medications will automatically pay when billed with the following diagnoses as listed below: ication (J code) Auto-pay ICD-9 codes Arzerra (J9302) 204.1, , , Avastin (J9035, C9257) Rituxan (J9310) , , , , , , , , , ( ), ( ), ( ), ( ), ( ), ( ), ( ), ( ), ( ), ( ), ( ), Lupron, Lupron Depot, Eligard (J1950, J9217, J9218) 185 IVIg (J1459, J1557, J1561, J1566, J1568, J1569, J1572, J1599) 446.1, Dacogen, Vidaza (J0894, J9025) 205.1, , , , Botox, Myobloc, Dysport, Xeomin (J0585, J0586, J0587, J0588) 333.6, 333.7, , , , , , , 334.1, 340, 341, 341.0, 341.1, 341.2, , 341.8, 341.9, 342.1, , 343, , 344.0, , 344.1, 344.2, 344.4, , 351.8, 378, , , , 530.0, 564.6, 565.0, 723.5, 854, 854.0, 854.1, , 952, ,
6 ical Reference Guide The following list of medications require preauthorization when administered by a health care professional. Drug Code Actemra J3262 Actimmune J9216 *Adcetris - non-institutional use J9999 *Adcetris - institutional use C9287 Amevive J0215 Arzerra J9302 Avastin C9257 Avastin J9035 Benlysta J0490 Berinert J0597 Boniva J1740 Botox J0585 Cimzia J0718 Cinryze J0598 Dacogen J0894 Dysport J0586 Eligard J9217 Erbitux J9055 Flebogamma J1572 *Flolan J1325 Gammagard J1569 Gammaplex J1557 Gamunex J1561 Gamunex-C J1561 H.P. Acthar Gel J0800 Halaven J9179 Herceptin J9355 Hizentra J1559 Istodax J9315 IVIg (NOS) J1599 IVIg Powder J1566 Jevtana J9043 Kalbitor J1290 Krystexxa J2507 Drug Code Lucentis J2778 Lupron Depot J1950 Lupron J9218 Macugen J2503 Makena J1725 Mozobil J2562 Myobloc J0587 Nplate J2796 Octagam J1568 Orencia J0129 Privigen J1459 ProliaTM J0897 Provenge Q2043 Qutenza J7335 Reclast J3488 Remicade J1745 Remodulin J3285 Rituxan J9310 Simponi J3590 Soliris J1300 Stelara J3357 Synagis Torisel J9330 Tysabri J2323 Vectibix J9303 *Veletri J1325 *Ventavis Q4074 Vidaza J9025 Vivaglobin J1562 Xeomin J0588 Xgeva J0897 Xolair J2357 Yervoy J9228 *New as of January 1,
7 Reminder of Pharmacy Updates for icaid and Family Health Plus As of October 1, 2011, BlueCross BlueShield of Western New York icaid and Family Health Plus (FHP) members began to receive their pharmacy benefits through BlueCross BlueShield instead of New York state. Their coverage will now follow the guidelines in our drug list. Please note that brand name prescription drugs that have a generic equivalent available are not included in the icaid/fhp formulary. Here are some the most commonly prescribed brand name medications that are no longer covered for these members, along with covered alternatives. Non-formulary medication Formulary alternatives* (no preauth requirement) Crestor Lipitor, simvastatin, lovastatin, pravastatin Lovaza fenofibric acid, gemfibrozil, niaspan Focalin XR Metadate CD, Ritalin LA, methylphenidate extended release tablet Vyvanse amphetamine/dextroamphetamine extended release Maxalt sumatriptan, naratriptan Relpax sumatriptan, naratriptan OxyContin Opana ER, morphine sulfate ER, fentanyl patch Abilify risperidone, Seroquel, paroxetine, sertaline Lyrica gabapentin, amitriptyline, venlafaxine, valproic acid Nexium omeprazole, lansoprazole, pantoprazole *Quantity limits may still apply 7
STAT Bulletin. Drug Therapy Guideline Updates. To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business
STAT Bulletin November 28, 2011 Volume 9: Issue 27 To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business Drug Therapy Guideline Updates Why you re receiving this Stat
More informationPharmacy and Medical Guideline Updates
STAT Bulletin PO Box 15013 Albany, New York 12212 August 2, 2010 Volume 8: Issue 19 To: All PCPs and Specialists Contracts Affected: All Lines of Business Pharmacy and ical Guideline Updates As a result
More informationSPECIALTY PHARMACY Master Clinical Drug List
Abraxane J9264 Provider ONCOLOGY None NO Actemra J3262 Provider ARTHRITIS PA - all YES Acthar HP Gel J0800 Prov/Self Med/Pharm ENDOCRINE/METABOLIC PA - all YES Adagen J2504 Provider ENZYME DISORDERS None
More informationPrescription Drug Benefit Rider
Prescription Drug Benefit Rider Your Certificate of Coverage is amended as described in this document. This Rider becomes a part of your Certificate of Coverage and is subject to all provisions of your
More informationPrescription Drug Benefit Rider V
Prescription Drug Benefit Rider V Your Certificate of Coverage is amended as described in this document. This Rider becomes a part of your Certificate of Coverage and is subject to all provisions of your
More informationDrug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015
J0129 Injection, abatacept (Orencia ), 10 J0178 Injection, aflibercept (Eylea ), 1 J0256 J0257 J0585 J0586 J0587 J0588 J0597 J0641 J0717 J0800 Injection, alpha 1-proteinase inhibitor, human (Aralast NP,
More informationMedStar Medicare Choice Pharmacy Services
Pharmacy Services 1 MedStar Medicare Choice Pharmacy Services Table of Contents At a Glance..page 2 Pharmacy Policies..page 4 Medicare Choice Pharmacy Programs..page 6 Where to Obtain Prescriptions..page
More informationPRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION
Abstral fentanyl citrate oral tablet Controlled Dangerous substance Actemra tocilizumab Monoclonal antibody Acthar corticotropin Hormone Actimmune interferon gamma 1b Interferon Actiq fentanyl citrate
More informationProvider Administered Drug Program (PADP) and Physician Administered Drug VPSS List
Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List Code Drug Name Effective and/or Term Date J0129 Injection, abatacept (Orencia ), 10 mg J0178 Injection, aflibercept (Eylea
More informationPRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION
Abstral fentanyl citrate oral tablet Controlled Dangerous substance Actemra tocilizumab Monoclonal antibody Acthar corticotropin Hormone Actimmune interferon gamma 1b Interferon Actiq fentanyl citrate
More informationBrand Generic J-Code 1 Billable. Exclusion Criteria. Information and Criteria. Unit
Affinity Health Plan Department Of Pharmacy (Medicaid, Child Health Plus, Family Health Plus, Medicare Part B) **Medications Requiring Authorization under Medical Benefit** Click Here For Medication Authorization
More informationPharmacy Services Request Types
FOR DRUG REQUESTS, ONLY-- * NOTE: Only those drugs administered by a healthcare provider and billed medically would be entered via CareAffiliate. * Oral drugs would not be administered by a healthcare
More informationBCBS AZ ADV PLUS * CLASSIC * PREMIER For use with members associated with the BHN Network Prior Authorization List 2015
Prior Authorization List 2015 Participating providers are responsible to furnish or arrange health care services with other participating healthcare facilities or providers. Prior authorization requests
More informationPA Category Name Code(s) Additional Notes ABA 0364T 0365T 0366T 0367T 0373T 0374T H G0396. Applied Behavioral Analysis stage 3*
ABA BEHAVIORAL HEALTH CHEMICAL DEPENDENCY Applied Behavioral Analysis stage 3* Neuropsychological Testing Chemical Dependency/Substance Abuse* (MA Only) 0364T 0365T 0366T 0367T 0373T 0374T H2020 96116
More informationHEALTHTEAM ADVANTAGE PLAN 2017 Step Therapy Criteria Pending CMS Approval
ARISTADA - ARISTADA INJ 441MG/1.6 ARISTADA INJ 662MG/2.4 ARISTADA INJ 882MG/3.2 CLAIM WILL PAY AUTOMATICALLY FOR ARISTADA IF ENROLLEE HAS A PAID CLAIM FOR AT LEAST A 1 DAYS SUPPLY OF ABILIFY MAINTENA AND
More informationStep Therapy Criteria
ADCIRCA ADCIRCA Coverage will be provided if the member has filled a prescription for sildenafil (at least a 30 day supply within the past 365 ) ELIDEL 76-F ELIDEL Coverage will be provided if the member
More informationNew Billing Guidelines for Home Infusion, Enteral and Parenteral Therapies Home Infusion Fee Schedule Effective July 1, 2009
STAT Bulletin PO Box 80 Buffalo, New York 14240-0080 May 12, 2009 Volume 15:Issue 18 To: All Home Health Care and Home Infusion Therapy Providers Contracts Effected: All Lines of Business New Billing Guidelines
More informationDIFICID. Products Affected Step 2: DIFICID TABLET 200 MG ORAL. Details
DIFICID DIFICID TABLET 200 MG ORAL Claim will pay automatically for Dificid if enrollee has a paid claim for at least a 1 days supply of vancomycin in the past. Otherwise, Dificid requires a step therapy
More informationADHD STIMULANTS-S(SHC)
Step Therapy Simply Health Care 2014 Formulary ID: 14406 Version: 14 Last Updated: 08/01/2014 ADHD STIMULANTS-S(SHC) Daytrana Focalin Xr Strattera Patient needs to have a paid claim for one Step 1 drug
More informationStep Therapy Approval Criteria
Effective Date: 01/01/2019 This document contains for the following medications: 1. Colcrys (colchicine) 2. Dovonex (calcipotriene) 3. Enbrel (etanercept) 4. Humira (adalimumab) 5. Imitrex Injection vial
More informationInjectable Drugs Requiring Pre-Service Approval
Abatacept Orencia J0129, 10 mg 1500 FL LCD- L29051 1) For patients with rheumatoid arthritis with failure, intolerance or contraindications to methotrexate. Limit dosing to 40 mg Q 2 weeks. 2) For patients
More informationHMSA Pharmacy Newsletter April 2006 For Participating Medical Practitioners
For Participating Medical Practitioners CDC HEALTH ALERT - USE OF ANTIVIRALS FOR INFLUENZA The U.S. Centers for Disease Control and Prevention (CDC) issued a Health Alert on January 14, 2006 regarding
More informationPHARMACY AND THERAPEUTICS COMMITTEE 4 th Quarter 2017
PHARMACY AND THERAPEUTICS COMMITTEE 4 th Quarter 2017 A meeting of the Health Partners Pharmacy and Therapeutics (P&T) Committee was held on September and December 2017. The following are the recommendations
More informationMETABOLIC, IMMUNE DISORDERS OR INHERITED RARE DISEASE ALPHA-1 PROTEINASE INHIBITORS ARANESP BLOOD CELL DEFICIENCY ARANESP ARCALYST
PRIOR AUTHORIZATION LIST (SUBJECT TO CHANGE) MEDICATION THERAPEUTIC CATEGORY MODULE ACTEMRA INFLAMMATORY CONDITIONS ACTEMRA ADCIRCA PULMONARY HYPERTENSION PDE-5 INHIBITORS FOR PAH ADDYI SEXUAL DISORDERS
More informationRationale for Decision Excluded Generic OTC equivalent available (Flonase Allergy Relief) Medicare status (if differs)
BLUE SHIELD OF CALIFORNIA FIRST QUARTER 2015 FORMULARY AND MEDICATION POLICY UPDATES EFFECTIVE MARCH 19, 2015 The Blue Shield of California (BSC) Pharmacy and Therapeutics (P&T) Committee, consisting of
More informationCARE N CARE HEALTH PLAN
ARISTADA ARISTADA PREFILLED SYRINGE 1064 MG/3.9ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 441 MG/1.6ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 662 MG/2.4ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 882
More informationStep Therapy Approval Criteria
Effective Date: 01/01/2018 This document contains Step Therapy Approval Criteria for the following medications: 1. Colcrys (colchicine) 2. Dovonex (calcipotriene) 3. Enbrel (etanercept) 4. Humira (adalimumab)
More informationCARE N CARE HEALTH PLAN
PPI DEXILANT CAPSULE DELAYED RELEASE 30 MG ORAL DEXILANT CAPSULE DELAYED RELEASE 60 MG ORAL Claim will pay automatically for Dexilant if enrollee has a paid claim for at least a 1 days supply of lansoprazole,
More informationARISTADA. Products Affected Step 2: ARISTADA PREFILLED SYRINGE 1064 MG/3.9ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 441 MG/1.
ARISTADA ARISTADA PREFILLED SYRINGE 1064 MG/3.9ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 441 MG/1.6ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 662 MG/2.4ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 882
More informationHEALTHTEAM ADVANTAGE 2018 Step Therapy Criteria
GLP1-INSULIN XULTOPHY SOLUTION PEN- INJECTOR 100-3.6 UNIT-MG/ML Claim will pay automatically for Xultophy if enrollee has a paid claim for at least a one day supply for step level 1 agent (LANTUS, LEVEMIR,
More informationAetna Better Health. Specialty Drug Program
Aetna Better Health is managed through CVS Health Specialty Pharmacy. The Specialty pharmacies fill prescriptions and ship drugs for complex medical conditions, including multiple sclerosis, rheumatoid
More informationHEALTHTEAM ADVANTAGE 2018 Step Therapy Criteria
GLP1-INSULIN XULTOPHY SOLUTION PEN- INJECTOR 100-3.6 UNIT-MG/ML HEALTHTEAM ADVANTAGE Claim will pay automatically for Xultophy if enrollee has a paid claim for at least a one day supply for step level
More informationCARE N CARE HEALTH PLAN
ARISTADA Aristada Prefilled Syringe 441 MG/1.6ML Intramuscular Aristada Prefilled Syringe 662 MG/2.4ML Intramuscular Aristada Prefilled Syringe 882 MG/3.2ML Intramuscular Claim will pay automatically for
More informationBRINTELLIX. Step Therapy Criteria HealthTeam Advantage Formulary ID: Version 6 Effective Date: 1/1/2016. PRODUCT(s) AFFECTED BRINTELLIX
BRINTELLIX BRINTELLIX Claim will pay automatically for brintellix if enrollee has a paid claim for at least a 1 days supply of any 2 generic formulary antidepressants in the past 365 days. Otherwise, brintellix
More informationMedical Prior Authorization List Rosen Employee Plans For prescription drug requirements, contact EHIM toll-free at
For prescription drug requirements, contact EHIM toll-free at 1.800.311.3446. General Information These requirements are administered by Health First Health Plans ( Health Plan ). Benefits are determined
More informationClinical Policy: Eltrombopag (Promacta) Reference Number: ERX.SPA.71 Effective Date:
Clinical Policy: (Promacta) Reference Number: ERX.SPA.71 Effective Date: 10.01.16 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationBLUE SHIELD OF CALIFORNIA JUNE 2016 PLUS DRUG FORMULARY CHANGES
BLUE SHIELD OF CALIFORNIA JUNE 2016 PLUS DRUG FORMULARY CHANGES Blue Shield is committed to covering safe, effective and affordable medications, so we regularly review and update our drug formularies.
More informationHMSA Pharmacy Newsletter February
HMSA s HMSA Pharmacy Newsletter February 2006 www.hmsa.com/portal/provider CDC HEALTH ALERT - USE OF ANTIVIRALS FOR INFLUENZA The U.S. Centers for Disease Control and Prevention (CDC) issued a Health Alert
More informationANTIDEPRESSANTS. Details. Step Therapy 2017 Last Updated: 5/23/2017
ANTIDEPRESSANTS EMSAM PATCH 24 HOUR 12 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 6 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 9 MG/24HR TRANSDERMAL FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG FETZIMA CAPSULE
More informationPulmonary Hypertension Weight Loss Skin Conditions. Skin Conditions Multiple Sclerosis Endocrine Disorder. Endocrine Disorder.
Prior Authorization PricewaterhouseCoopers The following medications may require prior authorization prior to dispensing at a participating retail pharmacy or through the Express Scripts Pharmacy home
More informationCost Effectiveness Recommendations For Kentucky Retirement Systems MTM Plan 2011
Medication Tier 2 options Tier 1 options Nexium- Tier 3 Aciphex Lansoprazole Omeprazole Pantoprazole Crestor- Tier 3 Lipitor Simvastatin Vytorin- Tier 3 Atacand- Tier 3 Avapro Benicar Cozaar Micardis Tevetan
More informationINJECTABLE MEDICINES. Resources, Links or Additional Information. J Code Brand Names Generic names Prior Authorization or Restrictions
J9190 5-FU fluorouracil None. J0401 ABILIFY MAINTENA aripiprazole i.v. J9264 ABRAXANE paclitaxel protein bound J3262 ACTEMRA IV tocilizumab Yes, through Navitus. Restricted to (in at least consultation
More informationStep Therapy Approval Criteria
Effective Date: 10/01/2016 This document contains Step Therapy Approval Criteria for the following medications: 1. Colcrys (colchicine) 2. Cymbalta (duloxetine) 3. Dovonex (calcipotriene) 4. Enbrel (etanercept)
More informationPA Category Name Code(s) Additional Notes ABA. Applied Behavioral Analysis stage 3*
ABA BEHAVIORAL HEALTH CHEMICAL DEPENDENCY Applied Behavioral Analysis stage 3* Neuropsychological Testing Chemical Dependency/Substance Abuse* (MA Only) 0373T H2020 96116 96112 96113 96121 96130 96131
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Promacta) Reference Number: CP.PHAR.180 Effective Date: 03.01.16 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important
More informationStep Therapy Approval Criteria
Effective Date: 07/01/2015 This document contains for the following medications: 1. Ambien CR (zolpidem ER) 2. Chantix Continuing Month (varenicline) 3. Chantix Starting Month (varenicline) 4. Cymbalta
More informationIHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT NOVEMBER 30, 2010
IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT201056 NOVEMBER 30, 2010 Changes to the Preferred Drug List Changes to the Preferred Drug List (PDL) were made at the November 19, 2010, Drug Utilization
More informationANTIDEPRESSANTS. Details. Step Therapy 2018 Last Updated: 8/21/2018
ANTIDEPRESSANTS EMSAM PATCH 24 HOUR 12 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 6 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 9 MG/24HR TRANSDERMAL FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG ORAL FETZIMA
More informationGenerics. Lead with. Prescription Step Therapy Program
Lead with Generics Prescription Step Therapy Program WWW.BCBSLA.COM 04HQ3972 R11/10 Blue Cross and Blue Shield of Louisiana incorporated as Louisiana Health Service & Indemnity Company GENERIC DRUGS: A
More information2016 MDwise HIP Medical Services that Require Prior Authorization
2016 MDwise HIP Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Requires PA Coding All Out of Network services Facility to facility ambulance
More information2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization AETA BETTER HEALTH MICHIGA Botulinum Toxins (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More informationORILISSA (elagolix) oral tablet
ORILISSA (elagolix) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationKentucky Department for Medicaid Services. Drug Review Options
Kentucky Department for Medicaid Services Drug Review Options The following chart lists the agenda items scheduled and the options submitted for review at the March 18, 2010 meeting of the Pharmacy and
More informationStep Therapy Medications
Step Therapy Medications Step Therapy (ST PA ) is an automated form of prior authorization. It encourages the use of therapies that should be tried first, before other treatments are covered, based on
More informationRelative Cost/Month. Less than $10. Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*
Allergy Chlorpheniramine Tablet* Diphenhydramine Tablet* Diphenhydramine Liquid* Loratadine Tablet* Cetirizine Tablet* Loratadine 10mg ODT* Less than $10 Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*
More informationUF Decision Report FY06-07 Beneficiary Advisory Panel 10 Jan 2008
UF Decision Report FY06-07 Beneficiary Advisory Panel 10 Jan 2008 Promoting high quality, cost effective drug therapy throughout the Military Health System UF Decisions, May 07 Class FY05 rank, total $
More informationSection I contains changes to the Highmark Select/Choice Formulary.
June 2007 2 nd Quarter Update: Highmark Drug Formulary Enclosed is the 2 nd Quarter 2007 update to the Highmark Drug Formulary and pharmaceutical management procedures. The Formulary and pharmaceutical
More informationPage: 1 of 6. Aimovig (erenumab-aooe) injection, Ajovy (fremanezumab-vfrm) injection, Emgality (galcanezumab-gnim)
Page: 1 of 6 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Last Review Date: November 30, 2018 Description Aimovig (erenumab-aooe) injection, Ajovy (fremanezumab-vfrm)
More information* Note: please reference the Highmark Health Options Gender Transition Services (MP- 033-MD-DE) policy for all gender dysphoria requests.
Request for Prior Authorization for Lupron, Lupron Depot (leuprolide acetate) Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Lupron (leuprolide acetate)
More information1. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Eligard Trelstar - Vantas (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationMDwise Hoosier Care Connect Medical Services that Require Prior Authorization
MDwise Hoosier Care Connect Medical Services that Require Prior Authorization Certain Indiana Health Coverage Programs (IHCP) services require prior authorization (PA) for members enrolled in the Hoosier
More informationCENTENE PHARMACY & THERAPEUTICS COMMITTEE SECOND QUARTER 2017 AMBETTER GUIDELINE SUMMARY. Revision Summary or Description
CENTENE PHARMACY & THERAPEUTICS COMMITTEE SECOND QUARTER 2017 AMBETTER GUIDELINE SUMMARY Coverage Guideline Policy & Procedure HIM.PA.32 Long acting stimulants (Adderall XR, Dexedrine, Metadate CD, Ritalin
More informationSpecialty Overview by Prior Authorization Approval or Denial 2nd Quarter 2016
Specialty Overview by Prior Authorization Approval or 2nd Quarter 2016 3961 DERMATOLOGY Humira RHEUMATOID ARTHRITIS Approval Approved from 04/13/2016 thru 04/13/2018 3961 DERMATOLOGY Stelara PSORIASIS
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Sprycel) Reference Number: CP.PHAR.72 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy
More informationMAXIMUM ALLOWABLE COST POLICY CHANGES DECEMBER 5, 2016 QUESTIONS AND ANSWERS
MAXIMUM ALLOWABLE COST POLICY CHANGES DECEMBER 5, 2016 QUESTIONS AND ANSWERS The November 22, 2016 Mid-Year Financial Report referred to changes to drug coverage under the Saskatchewan Drug Plan. What
More informationDate: October 3, 2017 To: Participating Providers From: YourCare Health Plan Provider Relations Subject: 2018 Formulary Changes
Date: October 3, 2017 To: Participating Providers From: YourCare Health Plan Provider Relations Subject: 2018 Formulary Changes 2018 Formulary-UM Changes What does this mean now, and for 2018? A number
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 5 Last Review Date: March 18, 2016 Xeljanz Description Xeljanz, Xeljanz
More informationModular Program Report
Modular Program Report The following report(s) provides findings from an FDA initiated query using its Mini Sentinel pilot. While Mini Sentinel queries may be undertaken to assess potential medical product
More informationSTEP THERAPY ALGORITHMS PUP Select Formulary
The Step Therapy drug will be dispensed if the drug has been dispensed within 120 days of current fill or if alternative (Step 1) drugs have been used first. If the member s prescription claim fails the
More informationOriginal Policy Date
MP 5.01.17 Specialty Drugs Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/ Date Local policy Last updated/12:2013 Return to Medical Policy Index
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 5 Last Review Date: March 17, 2017 Xeljanz Description Xeljanz, Xeljanz
More informationPharmacy Prior Authorization Clinical Guideline for Attention Deficit Disorder/Attention Deficit Hyperactivity CNS Stimulants
AETNA BETTER HEALTH Pharmacy Prior Authorization Clinical Guideline for Attention Deficit Disorder/Attention Deficit Hyperactivity CNS Stimulants Formulary amphetamine/dextroamphetamine IR, ER (generic
More informationGenerics. Lead with. P r e s c r i p t i o n S t e p T h e r a p y P r o g r a m
Lead with Generics P r e s c r i p t i o n S t e p T h e r a p y P r o g r a m WWW.BCBSLA.COM 04HQ3972 5/09 Blue Cross and Blue Shield of Louisiana incorporated as Louisiana Health Service & Indemnity
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE February 18, 2015 SUBJECT EFFECTIVE DATE January 21, 2015 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Drug List (PDL) Update January 21, 2015 Pharmacy Services Vincent D. Gordon, Deputy
More information2016 MDwise HIP Medical Services that Require Prior Authorization
2016 MDwise HIP Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Coding All Out of Network services Facility to facility ambulance transport
More informationERLEADA (apalutamide) oral tablet
ERLEADA (apalutamide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationDrugs That Require Prior Authorization (PA) Before Being Approved for Coverage
Drugs That Require Prior Authorization (PA) Before Being Approved for Coverage You will need authorization by your UA Medicare Part D Prescription Drug Plan before filling prescriptions for the drugs shown
More informationWith prescription therapies at the center of more Americans health care, these medications have become invaluable. costs. Despite the 1.6% 1.2% 0.
Rx spending up, but challenges remain By Richard Monks No products play a greater role in setting drug stores and community pharmacies apart from other retailers than prescription drugs. One % prescription
More informationQuarterly Pharmacy Formulary Change Notice
MEDICAID PROVIDER BULLETIN February 26, 2015 Quarterly Pharmacy Formulary Change Notice Summary of Change: The formulary changes listed in the table below were reviewed and approved at our September 24,
More information2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization MERC CARE PLA (MEDICAID) Botulinum Toxins (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and
More informationPPHP 2017 Formulary 2017 Step Therapy Criteria
ARISTADA Aristada Prefilled Syringe 1064 MG/3.9ML Intramuscular Aristada Prefilled Syringe 441 MG/1.6ML Intramuscular Aristada Prefilled Syringe 662 MG/2.4ML Intramuscular Aristada Prefilled Syringe 882
More informationDrug Bill As Unit Common Directions Common Day Supply Common Billing Errors Oral Tablets/Capsules
Note: This is a guide for commonly misbilled medications. Please submit the claims according to directions for use indicated on the prescription order. Drug Bill As Unit Common Directions Common Day Supply
More informationPremera Blue Cross Medicare Advantage Plans Medical Policy Updates
Premera Blue Cross Medicare Advantage Plans Medical Policy Updates Medical Policy and Criteria Premera Blue Cross Medicare Advantage reviews all medical policies and criteria annually. The following updates
More informationMarch 2017 Pharmacy & Therapeutics Committee Decisions
UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to the UCare formulary (approved drug list). These changes are reviewed
More informationPrescription Drug Benefit Rider
Prescription Drug Benefit Rider Your Certificate of Coverage is amended as described in this document. This Rider becomes a part of your Certificate of Coverage and is subject to all provisions of your
More information2019 Formulary Update
MEDICARE ADVANTAGE BlueShield of Northeastern New York Formulary Update BlueShield of Northeastern New York has updated its formulary (drug list) since its original publication in January. This document
More informationCommercial Formulary and Utilization Management Program Updates for January 2017 Producer Communication #782 Issued November 10, 2016
Commercial and Utilization Management Program Updates for January 2017 Producer Communication #782 Issued November 10, 2016 Message The Capital BlueCross Pharmacy & Therapeutics (P&T) Committee, consisting
More informationDrug Formulary Update, January 2013
Drug Formulary Update, January 2013 Updates to the HealthPartners Drug Formularies are listed below. Updates for the Commercial Drug Formularies and the Minnesota Health Care Programs (Medicaid and Minnesota
More informationNovember 2018 P & T Updates
November 2018 P & T Updates Commercial Triple Tier 4th Tier Applicable Traditional Prior Auth AIMOVIG 3 2 Detailed s 70 mg per month: 2 ml per 60 days 140 mg per month: 2 ml per 30 days AJOVY 3 2 4.5 ml
More informationSTEP THERAPY CRITERIA
STEP THERAPY This is a complete list of drugs that have written coverage determination policies. Drugs on this list do not indicate that this particular drug will be covered under your medical or prescription
More informationContents Please refer to Medical Policy I-40 Pertuzumab (Perjeta) for additional information.
May 2018 In This Issue Coverage Guidelines Revised for Azacitidine (Vidaza)... 3 Coverage Guidelines Revised for Fulvestrant (Faslodex)... 4 Place of Service Revised for Total Hip and Total Knee Arthroplasty...
More informationClinical Policy: Lisdexamfetamine (Vyvanse) Reference Number: CP.PMN.121 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Vyvanse) Reference Number: CP.PMN.121 Effective Date: 02.01.09 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More information